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Studies have demonstrated overproduction of prostaglandin E2 (PGE2) in CF. In
vitro study show that alterations in CFTR are involved in overproduction of PGE2.
Findings that suggest that measurement of PGE2 production may help to assess the
severity of the altered regulation of CFTR and intensity of inﬂammatory process
in the airways of CF patients. Tetranor PGEM (PGE-M) is a metabolite present in
urine that accurately reﬂects the biosynthesis of the PGE2. In this study we assessed
the relationship between levels of PGE-M with CF severity.
Methods: 36 patients with stable CF and 24 healthy controls were recruited.
All CF patients had undergone evaluation of pancreatic function, lung function
by spirometry and genotype severity. PGE-M levels were measured by a liquid
chromatographic/mass spectrometric assay.
Results: PGE-M concentrations were markedly and signiﬁcantly elevated
(p< 0.0001) in the urine of CF patients (34.5±45 ng/mgCr) compared with healthy
controls (7.4±4.25 ng/mgCr). There was no correlation between PGE-M urinary
levels and spirometric values. In patients with pancreatic insufﬁciency there was
a higher PGE-M urinary level (38±7 ng/mgCr) than in patients with conserved
pancreatic function (10±4.6 ng/mgCr) (p = 0.05). There was an association of the
severity of genotypes with levels of PGE-M: mild: 8.6±4.1 ng/mgCr; moderate:
19.7±11 ng/mgCr; severe: 48±53.3 ng/mgCr (p< 0.0027).
Conclusions: Measurement of urinary PGE-M may be a useful tool to investigate
severity of CF and to assess the efﬁcacy of any therapy aimed to improve the
function of a defective CFTR.
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Cystic Fibrosis (CF)-related diabetes (CFRD), the most common complication
of CF, is preceded by a phase of low insulin secretion, glucose intolerance and
accelerated decrease in weight and pulmonary function. However, no study has
shown a direct link between systemic inﬂammation, clinical deterioration and the
occurrence of CFRD in adult patients with CF.
Objective: The aim of this study was to determine if interleukin (IL)-6, an important
inﬂammatory mediator in CF as well as in diabetes, was associated to CFRD
pathology.
Methods: This cross-sectional study included 88 adult patients with CF (47 with
normal glucose tolerance (NGT) and 41 with de novo CFRD, as determined by
the oral glucose tolerance test) with a mean age of 29.7±8.4 years, an average
body mass index (BMI) of 22.0±3.5 (kg/m2) and %FEV1 of 70.1±21.9, from the
Montreal CF cohort (Hoˆtel-Dieu CHUM, Montreal, Canada).
Conclusions: There was no difference in plasma levels of IL-6, as measured
by enzyme-linked immunosorbent assay, between patients with NGT and with
CFRD. Also, plasma IL-6 was associated to neither insulin (secretion or sensitivity)
nor glucose (glucose excursion during OGTT or glycated hemoglobin) indexes
of homeostasis. However, high levels of IL-6 were independently associated to
pulmonary function impairment (P< 0.01), low BMI (P< 0.05) and high levels of
subclinical markers of inﬂammation, such as C-reactive protein (P< 0.01), ﬁbrino-
gen (P< 0.01), white blood cells (P< 0.01) and neutrophils (P< 0.01). Although
IL-6 appears to be an important biomarker in CF-related clinical degradation, the
onset of CFRD does not seem to increase its level in stable patients with CF.
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Background: Autoimmune antibodies (Ab) can be found in up to 80% of
CF patients prior to lung transplantation and anti-neutrophil cytoplasmic antibodies
(ANCA) may be associated with severity of lung disease and disease prognosis [1].
In this pilot study, we investigated the prevalence of autoimmune antibodies in
CF patients after lung transplantation (LuTx).
Methods: Consecutive patients attending our outpatient clinic were screened for
a wide range of autoantibodies in serum (ANA, AMA, SMA, EMA, TTG Ab,
p-ANCA, c-ANCA, ASCA, SLA, LC-1 Ab), as well as immunoglobulins (IgG,
IgA and IgM). Autoimmune diseases were excluded.
Results: 36 patients (median age 30 y, IQR 25−38 y; 42% male) were included in the
study. Median time since LuTx was 4.5 y (IQR: 2.3−8.3 y). IgG levels were elevated
in 8% (3/36) of patients. Overall prevalence of autoantibodies was 83%. However,
only 12% (4/34) of patients had elevated ANAs, only one patient tested positive for
SMAs. Of note, 83% (24/29) of patients had elevated anti-saccharomyces cerevisiae
antibodies (ASCA). Of these, 4 of 24 ASCA IgG only, in 8 of 24 ASCA IgA only,
and in 12 of 24 both were positive. Yet, in none of the patients neither AMA, EMA,
TTG Ab, SLA, LC-1 Ab, nor ANCA were detected.
Conclusion: In contrast to published data in CF patients pre LuTx, ANCA were
not found in patients post LuTx. ASCAs were the dominant fraction in our panel
of autoantibodies. Association with clinical outcomes are part of this ongoing trial.
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Objectives: Annual ﬂu vaccination is strongly recommended to patients with
cystic ﬁbrosis (CF). In 2009, H1N1 vaccination was also recommended in at-
risk categories. Several strategies to improve H1N1 vaccination were applied, with
heterogeneous and often unsatisfactory results.
Aim: To assess how the management of vaccination against pandemic and seasonal
ﬂu might have conditioned the adherence to the H1N1 immunization in at-risk
children.
Methods and Results: 161 children (CF, n = 35; HIV infection, HIV, n = 34; type
I diabetes mellitus, DM, n = 34; neuromuscular disease, NNMD, n = 34; Down
syndrome, DS, n = 24) were enrolled. 95 (59%) patients had received ﬂu vaccination
in 2008–2009 season and 120 (74%) in 2009–2010 (p< 0.05). CF was the category
better vaccinated in both seasons. 48% of patients received H1N1 vaccine. The
highest vaccination rate was registered in CF (83%) and HIV (82%), with a rate of
31% in the other categories (p< 0.05). The main reason to be vaccinated against
H1N1 was recommendation by physicians of the Reference Center (RC) in case of
CF and HIV. 14/35 (40%) CF and almost all (97%) HIV children received H1N1
vaccination at the RC, versus only 4% of the other categories.
Conclusion: Developing speciﬁc communication strategies and enhancing compli-
ance with the ofﬁcial recommendations is important to improve immunization in
at-risk patients and identify barriers to local vaccine implementation. The H1N1
experience should be taken into account for planning future vaccination campaigns.
Centralization of the immunization at the Reference Centers for chronic diseases,
as in case of CF, may represent a key strategy to improve ﬂu vaccination coverage.
